2-氨基-4-甲基戊酸盐酸盐 | 6322-53-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 天然氨基酸及其衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-4-甲基戊酸盐酸盐
• 中文别名: 2-氨基-4-甲基戊酸甲酯盐酸盐；4-氯-2-丁酮；亮氨酸甲酯盐酸盐(1:1)；DL-亮氨酸甲酯盐酸盐
• 英文名称: leucine methyl ester hydrochloride
• 英文别名: methyl leucinate hydrochloride；DL-leucine methyl ester hydrochloride；cycloleucine methyl ester hydrochloride；Hydron;methyl 2-amino-4-methylpentanoate;chloride
• CAS: 6322-53-8
• 化学式: C₇H₁₆NO₂*Cl
• mdl: MFCD00067541
• 分子量: 181.663
• InChiKey: DODCBMODXGJOKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.82
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S36/37
• 危险类别码：
  R43
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-DL-Leu-OMe HCl
Synonyms: DL-Leucine methyl ester hydrochloride

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-DL-Leu-OMe HCl
CAS number: 6322-53-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H16ClNO2
Molecular weight: 181.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-4-甲基戊酸盐酸盐 在 碳酸氢钠 、 三乙胺 、 三氯氧磷 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 50.0h， 生成 甲基2-异氰基-4-甲基戊酸酯
  参考文献：
  名称：

  使用乙酰丙酸的乌吉三组分反应作为双功能底物，胺和氨基酸基异氰酸酯合成新型伪肽

  摘要：

  据报道，通过乙酰丙酸（4-氧戊酸），芳香族和脂肪族胺以及氨基酸基异氰酸酯的分子内Ugi反应合成了一类新型的假肽。左旋丙酸被用作含有适合于Ugi反应的羰基和酸部分的双功能底物。本文为合成含有2-吡咯烷酮（γ-内酰胺），酰胺和酯官能团的肽样杂环分子提供了一种简便易行的一锅法，产率高到优。

  DOI：

  10.3762/bjoc.15.82
• 作为产物：
  描述：

  甲醇 、 DL-亮氨酸 在 氯化亚砜 作用下， 以56 %的产率得到2-氨基-4-甲基戊酸盐酸盐
  参考文献：
  名称：

  光化学脱消旋反应机理的多方面观点

  摘要：

  在手性二苯甲酮催化剂 (5 mol %) 存在下照射时，给定手性咪唑啉-2,4-二酮（乙内酰脲）的外消旋混合物几乎可以定量地转化为具有高对映体过量的相同化合物（80–99 % ee). 这种光化学脱外消旋反应的机理已通过一系列机理实验阐明。核磁共振滴定证实催化剂通过两点氢键结合两种对映异构体。在其中一种非对映异构体配合物中，立体异构碳原子上的氢原子理想地定位于氢原子转移 (HAT) 至光激发的二苯甲酮。通过瞬态吸收检测质子化的羰基自由基表明氢提取只发生在一个而不是另一个乙内酰脲对映异构体中。量子化学计算使我们能够在这个复合物中可视化 HAT，更重要的是，表明后 HAT 不会发生在乙内酰脲自由基的碳原子上，而是发生在它的氧原子上。在此过程中形成的非手性烯醇可以通过其在 λ ≅ 330 nm 处的特征瞬态吸收信号直接监测。随后的互变异构化导致两种乙内酰脲对映体，但其中只有一种返回催化循环，从而

  DOI：

  10.1021/jacs.2c11265

文献信息

• Heterocycles as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5-(acylamino)oxazoles as intermediates en route to the cyclopeptide alkaloids
  作者：Bruce H. Lipshutz、Randall W. Hungate、Keith E. McCarthy

  DOI：10.1021/ja00364a041

  日期：1983.12

  Etude de la synthese de dialkyl-2,4 acylamino-5 oxazoles par cyclisation a partir d'α-cyanoalkylamides d'acides, de N-acetyl α-aminoamides ou de dipeptides. Fonctionnalisation des oxazoles obtenus

  从二烷基-2,4 酰基氨基-5 恶唑环化到部分 d'α-氰基烷基酰胺 d'酸、去 N-乙酰 α-氨基酰胺或二肽合成练习曲。钝性恶唑功能化
• DERIVATIVES OF IMIDAZO PYRIMIDO AND DIAZEPINE PYRIMIDINE-DIONE, AND USE THEREOF AS A DRUG
  申请人：Poitout Lydie

  公开号：US20100144714A1

  公开（公告）日：2010-06-10

  The present invention relates to new derivatives of imidazo, pyrimido and diazepine-pyrimidine-dione of the general formula (I) in which R 1 , R 2 , L 1 , L 2 , Y, Z and A are various and varying groups. These products exhibit a good affinity for certain sub-types of cannabinoid receptors, in particular the CB2 receptors. They are particularly useful for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also relates to pharmaceutical compositions containing said products, and to the use thereof for preparing a drug.

  本发明涉及通式（I）中的新咪唑，嘧啶和二氮杂吡咯啉-嘧啶二酮衍生物，其中R1，R2，L1，L2，Y，Z和A是各种不同的基团。这些产物对特定类型的大麻素受体，特别是CB2受体具有良好的亲和力。它们特别适用于治疗涉及一个或多个大麻素受体的病理状况和疾病。该发明还涉及含有上述产物的药物组合物，以及用于制备药物的使用。
• PEPTIDE TURN MIMETICS
  申请人：Cassidy Peter Joseph

  公开号：US20110040087A1

  公开（公告）日：2011-02-17

  Peptide mimetics of structure X herein which (i) provide a wide range of sidechain functions at all sidechain positions, (ii) can be incorporated in a peptide sequence, (iii) can be readily synthesized and (iv) have a variety of conformations. There is also provided a novel process which can provide valuable intermediates in relation to production of peptide mimetics of structure X which intermediates have a high degree of chemo- and stereo-selectivity. Preferred mimetics include structures I, II, III, IV, V and VI.

  本文中的结构X的肽类拟体具有以下特点：(i) 在所有侧链位置提供广泛的侧链功能，(ii) 可以被纳入肽序列中，(iii) 可以被轻松合成，(iv) 具有多种构象。还提供了一种新的过程，可以提供与结构X的肽类拟体的生产相关的有价值的中间体，这些中间体具有高度的化学和立体选择性。首选的拟体包括结构I、II、III、IV、V和VI。
• New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2
  作者：Amanda do Rocio Andrade Pires、Florine Lecerf-Schmidt、Nathalie Guragossian、Jaqueline Pazinato、Gustavo Jabor Gozzi、Evelyn Winter、Glaucio Valdameri、Alexander Veale、Ahcène Boumendjel、Attilio Di Pietro、Basile Pérès

  DOI：10.1016/j.ejmech.2016.05.053

  日期：2016.10

  Breast cancer resistance protein (BCRP/ABCG2) is one of the major transporters involved in the efflux of anticancer compounds, contributing to multidrug resistance (MDR). Inhibition of ABCG2-mediated transport is then considered a promising strategy for overcoming MDR in tumors. We recently identified a chromone derivative, namely MBL-II-141 as a selective ABCG2 inhibitor, with relevant in vivo activity

  乳腺癌抗性蛋白（BCRP / ABCG2）是参与抗癌化合物外排的主要转运蛋白之一，有助于多药耐药性（MDR）。然后，认为抑制ABCG2介导的转运可克服肿瘤中的MDR。我们最近鉴定了一种色酮衍生物，即MBL-II-141，作为一种选择性ABCG2抑制剂，具有相关的体内活性。在这里，我们报告了MBL-II-141的药物代谢，目的是鉴定关键药效学元素，以设计更有效的选择性和无毒抑制剂。通过使用简单且负担得起的化学方法对MBL-II-141进行合理的结构修饰，我们获得了活性高且易于制备的ABCG2抑制剂。在研究的化合物中，衍生物4a，发现其效价比MBL-II-141强3倍。它与参考抑制剂Ko143类似地有效，但具有较低的固有细胞毒性优势，因此构成有史以来报道的显示出极高治疗率的最佳ABCG2抑制剂。
• [EN] PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS<br/>[FR] PYRIDIN-2-AMIDES UTILES COMME AGONISTES DE CB2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012168350A1

  公开（公告）日：2012-12-13

  The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  本发明涉及式(I)的化合物，其中R1至R4的定义如描述和权利要求中所述。式(I)的化合物可以用作药物。